Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,947 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Colon and Rectal Diseases Clear all

Conditions: Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Interventions: Not listed
Lead sponsor: Luventix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Encinitas, California • Santa Monica, California • Walnut Creek, California

Conditions: Adenocarcinoma, Colon Cancer
Interventions: XELOX, XELIRI, Bevacizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 12
States / cities: Deerfield Beach, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 8 more

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pancreatic Cancer
Interventions: MGC030; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: fluorouracil, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 20
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more

Conditions: Neoplasms
Interventions: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more

Conditions: Colorectal Cancer, Rectal Cancer, Colon Cancer, Colon Rectal Cancer, Rectal Neoplasms, Colon Adenocarcinoma, Hereditary Nonpolyposis Colon Cancer
Interventions: Colorectal Cancer Educational Videos in Spanish; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Colorectal Neoplasms, Diverticulitis, Inflammatory Bowel Diseases, Surgical Site Infection
Interventions: Polyethylene Glycol, Neomycin, Metronidazole Hydrochloride, Therapeutic Conventional Surgery; Drug · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 19 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colorectal Cancer
Interventions: Racial group-targeted messages, Explicit Commitment; Other
Lead sponsor: Oakland University; Other
Eligibility: 45 Years to 80 Years
Enrollment: 799 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Michigan

Conditions: Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions: Prevention Care Management; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years to 64 Years · Female only
Enrollment: 2,241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions: XmAb®22841, Pembrolizumab (Keytruda®); Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer
Interventions: JANX008; Drug
Lead sponsor: Janux Therapeutics; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 18
States / cities: Duarte, California • Sacramento, California • San Diego, California + 15 more

Conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Interventions: BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI); Drug
Lead sponsor: Bold Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Santa Monica, California • Tampa, Florida

Conditions: Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions: CB-839, Talazoparib; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more

Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia, Multiple Myeloma
Interventions: internet-based intervention, assessment of therapy complications, Questionnaire Administration; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 95
States / cities: Castro Valley, California • Fremont, California • Martinez, California + 63 more

Conditions: Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2015
U.S. locations: 1
States / cities: Duarte, California

Conditions: Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
Interventions: enadenotucirev, nivolumab; Biological
Lead sponsor: Akamis Bio; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Tucson, Arizona • Duarte, California • Santa Monica, California + 3 more

Conditions: Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Interventions: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colorectal Carcinoma, Lynch Syndrome
Interventions: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Interventions: Test for circulating tumor cells, DNA alterations; Diagnostic Test
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
Interventions: Stool Sample Collection Kit; Device
Lead sponsor: Exact Sciences Corporation; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 21
States / cities: Newport Beach, California • Hamden, Connecticut • Holiday, Florida + 17 more

Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Interventions: JDQ443, TNO155, tislelizumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more

Conditions: Colorectal Neoplasms
Interventions: 5-fluorouracil, bevacizumab, capecitabine, irinotecan, folinic acid, oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 45
States / cities: Mobile, Alabama • Long Beach, California • Los Angeles, California + 41 more

Search by objective public record fields.

Urine Metabolites in the Diagnosis of Disease

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Study of MGC030 in Participants With Advanced Solid Tumors

Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

PeLear CCC: Proyecto Latino Contra Cancer Colorrectal

Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery

Colorectal Cancer Screening Intervention Study

Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer